Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has fully enrolled Part 2 of the critical three-part PF614-MPAR-102 clinical study to study the effect of food on the MPAR technology.PF614-MPAR has earned the FDA's prestigious Breakthrough Therapy...
Read more








